Revenue from India business rose 12 per cent to Rs 3,452 crore Ebitda declined 33 per cent YoY to Rs 1,192 crore and margins contracted by 890 basis points to 16.7 per cent from 25.6 per cent in Q1 FY26
doi: 10.1007/s40258-021-00705-w
10.1056/NEJMoa2028395 71 NguyenA
However, Victoria Divino, director of epidemiology at Novo Nordisk, said data are limited as to whether the GLP-1 medication can lower CV risk among adults without prior CVD
FDA Access Data+1 In 2025, the FDA expanded Ozempics label to include reducing the risk of kidney disease progression and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, based on the FLOW trial
Contribution of antioxidants to preventive effect of mesna in cyclophosphamide-induced hemorrhagic cystitis in rats